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Abstract
Background: Smoking has been identified in observational studies as a risk factor for bacterial vaginosis (BV), a
condition defined in part by decimation of Lactobacillus spp. The anti-estrogenic effect of smoking and trace
amounts of benzo[a]pyrene diol epoxide (BPDE) may predispose women to BV. BPDE increases bacteriophage
induction in Lactobacillus spp. and is found in the vaginal secretions of smokers. We compared the vaginal
microbiota between smokers and non-smokers and followed microbiota changes in a smoking cessation pilot study.
Methods: In 2010–2011, 20 smokers and 20 non-smokers were recruited to a cross-sectional study (Phase A) and 9
smokers were enrolled and followed for a 12-week smoking cessation program (Phase B). Phase B included weekly
behavioral counseling and nicotine patches to encourage smoking cessation. In both phases, participants self-collected
mid-vaginal swabs (daily, Phase B) and completed behavioral surveys. Vaginal bacterial composition was characterized
by pyrosequencing of barcoded 16S rRNA genes (V1-V3 regions). Vaginal smears were assigned Nugent Gram stain
scores. Smoking status was evaluated (weekly, Phase B) using the semi-quantitative NicAlert® saliva cotinine test and
carbon monoxide (CO) exhalation.
Results: In phase A, there was a significant trend for increasing saliva cotinine and CO exhalation with elevated Nugent
scores (P value <0.005). Vaginal microbiota clustered into three community state types (CSTs); two dominated by
Lactobacillus (L. iners, L. crispatus), and one lacking significant numbers of Lactobacillus spp. and characterized by
anaerobes (termed CST-IV). Women who were observed in the low-Lactobacillus CST-IV state were 25-fold more likely
to be smokers than those dominated by L. crispatus (aOR: 25.61, 95 % CI: 1.03-636.61). Four women completed Phase
B. One of three who entered smoking cessation with high Nugent scores demonstrated a switch from CST-IV to a
L.iners-dominated profile with a concomitant drop in Nugent scores which coincided with completion of nicotine
patches. The other two women fluctuated between CST-IV and L. iners-dominated CSTs. The fourth woman had low
Nugent scores with L. crispatus-dominated CSTs throughout.
Conclusion: Smokers had a lower proportion of vaginal Lactobacillus spp. compared to non-smokers. Smoking cessation
should be investigated as an adjunct to reducing recurrent BV. Larger studies are needed to confirm these findings.
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Background
Cigarette smoking is strongly associated, and often
found in a dose-dependent relationship, with risk of bac-
terial vaginosis (BV) [1-12]. The relationship persists
after controlling for other known confounders such as
sexual behaviors and alcohol use [13]. BV is a common
clinical syndrome in which the protective lactic acid-
producing bacteria, mainly species of the Lactobacillus
genus, are in low relative abundance and are supplanted
by a diverse array of anaerobic bacteria [14]. BV sufferers
frequently report morbidity, including vaginal odor and
irritation, [15] emotional, sexual, and social impacts, [16]
and are at higher risk for sexually transmitted infections
upon exposure [17]. Conventional therapy consists of
nitoimidazoles or clindamycin administered orally or
topically [15]. Unfortunately, BV can be highly recurrent
[18] with over 50% of women experiencing a symptom-
atic relapse within 3–12 months following antibiotic
therapy [19]. An unexplored intervention for BV is
smoking cessation.
Bagaitkar et al. cite three mechanisms by which to-
bacco affects bacterial infections across the human body:
physiological and structural changes, increase in bacter-
ial virulence, and dysregulation of immune function [20].
Nicotine and its metabolite cotinine have been detected
in the cervical mucus of smokers [21-23]. It is also hy-
pothesized that smoking leads to an accumulation of
vaginal amines, [21] which combined with the antiestro-
genic effect of smoking [24] predisposes a woman to BV.
Women who smoke have significantly lower levels of
mid-cycle and luteal phase estradiol compared with non-
smokers, [24] and it is well documented that the vaginal
microenvironment is influenced by endogenous estrogen
[25-27]. In addition, trace amounts of benzo[a]pyrene
diol epoxide (BPDE) are found in the vaginal secretions
of women who smoke and BPDE significantly increases
bacteriophage induction in lactobacilli [28]. Smoking
may then reduce the abundance of protective vaginal
lactobacilli in part by promoting phage induction.
We hypothesize that the composition of vaginal bac-
terial communities (termed the vaginal microbiota) is
strongly affected by smoking. In this study we compared
the vaginal microbiota, as determined by 16S rRNA gene
sequencing, between smokers and non-smokers, and we
also followed changes in the vaginal microbiota over
time in a pilot study of smoking cessation.
Methods
This manuscript details two separate Phases in our smok-
ing study. The first (Phase A) was a cross-sectional study
in which smokers and non-smokers were compared at a
single time point. The second (Phase B) was a longitudinal
study in which a subgroup of smokers from Phase A were
recruited to a smoking cessation pilot study.
Phase A: cross-sectional study
In 2010–2011, 20 smokers and 20 non-smokers were re-
cruited to a cross-sectional study (single visit) at the Cen-
ter for Health Behavior Research (CHBR) at the University
of Maryland School of Public Health (UMSPH). Inclusion
criteria were non-pregnant, non-lactating women, aged 18
to 45 years. Women had to be healthy as determined by
medical history, with absence of acute or chronic illnesses,
including serious psychiatric disorders or current depres-
sion. In addition, participants were excluded if they had
used an antibiotic or antimycotic in the prior 30 days or
reported a known history of other drug or alcohol de-
pendence in the prior 12 months. Current smoking status
was determined by self-report and confirmed by carbon
monoxide (CO) exhalation and saliva cotinine measures
(described below). Non-smokers also denied smoking in
the prior year. Participants completed questionnaires on
demographics, nicotine withdrawal, smoking urges, smok-
ing history and tobacco use behavior, depression, nicotine
dependence, and reproductive health history.
In a private clinic room, participants self-collected two
mid-vaginal swabs (Copan flocked nylon elution-swab
and Starplex double headed rayon swab), measured their
vaginal pH using the VpH glove (Inverness Medical) and
prepared a vaginal smear on a slide for Nugent Gram-
stain analysis [29]. The Nugent score reflects the relative
abundance of large Gram-positive rods (lactobacilli),
Gram-negative and Gram-variable rods and cocci (i.e.,
G. vaginalis, Prevotella, Porphyromonas, and peptostrep-
tococci), and curved Gram-negative rods (i.e., Mobiluncus).
This technique allows assessment of relative numbers of
bacteria, allowing for classification of bacterial load. It is
based on a linear scale ranging from 0–10. A score of 0–3
is considered normal, 4–6 is an intermediate state, and
7–10 is indicative of BV.
Self-collection of mid-vaginal swabs for microbiota
analysis has been validated in several studies comparing
self-collected to clinician-collected samples [30-32]. We
have also validated the use of a home freezer (−20°C) in
a vaginal microbiota study which compared cold chain
protocols [33].
Phase B: a pilot longitudinal study of smoking cessation
Phase B participants (n = 9) were recruited using the same
criteria as Phase A. Additional inclusion criteria for the
Phase B smoking cessation trial were being a current
smoker who smoked at least 10 cigarettes/day, no re-
ported period of smoking abstinence greater than three
months in the prior year, no history of hypersensitivity to
nicotine or adhesives, and motivation to quit smoking.
Participants completed questionnaires on demographics,
nicotine withdrawal, smoking urges, smoking history and
current behavior, depression, nicotine dependence, and re-
productive health history at their baseline visit.
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Daily procedures at the participant’s home
Each day for the 12-week study, participants self-collected
two mid-vaginal swabs (Copan flocked nylon elution-
swab and Starplex double headed rayon swab), mea-
sured their vaginal pH (VpH glove, Inverness Medical)
and prepared a vaginal smear on a slide for Nugent
Gram stain analysis [29]. The two vaginal swabs were
stored at the participants’ home in the freezer and
the smear was stored in a slide container at room
temperature. Participants transported samples to the
CHBR weekly in coolers with cold packs to maintain
frozen samples. The participants also completed daily
diaries which documented time-varying factors includ-
ing sexual activities, menstrual cycle, feminine hygiene,
smoking and nicotine patch use.
Weekly procedures at the study site
All participants received one-on-one behavioral counsel-
ing each week [34] that consisted of an initial 20-minute
session focused on setting the target quit date and pre-
paring to quit (baseline visit) and approximately 10-
minute weekly sessions thereafter, focused on quitting or
preventing relapse. Participants were given a modified
copy of the National Cancer Institute’s booklet entitled
“Clearing the Air”, a take-home aid for individuals in
smoking cessation programs [35].
During the first ten weeks of the study, participants
were asked to use Nicoderm CQ® patches daily as an aid
to quitting smoking and were individually trained on
proper patch application by the study staff. Participants
stepped down the nicotine patch levels according to a
known efficacious dosing schedule: a 21 mg patch in
weeks 1 to 6, 14 mg patch in weeks 7 to 8, and 7 mg
patch in weeks 9 to 10 [36]. There was no prescribed
patch use in weeks 11–12 which represented a two-week
nicotine-free observation period. At each weekly visit,
smoking status and patch use was verified using saliva
cotinine and CO measurements.
All participants in Phase A and Phase B provided writ-
ten informed consent. Ethical approval was obtained
from the Institutional Review Boards of the University of
Maryland Baltimore (UMB) and the UMSPH.
Biomarkers of smoking
Smoking status was evaluated using both the semi-
quantitative NicAlert® saliva cotinine test and Bedfont
Micro Smokerlyzer® to measure CO exhalation [37-40].
Breath CO has a 5-6- hour half-life so it is accurate in de-
tecting a 24-hour time frame [41]. The half-life for cotin-
ine is approximately 20 hours and therefore can identify
longer term abstinence [42]. The cotinine test can detect
six levels of concentrations from 0 to 2000+ ng/ml. In this
study, a CO of greater than 8 parts per million (ppm) and
a cotinine measurement of greater than 200 ng/ml defined
a smoker. When a participant has quit smoking and is ac-
tively using the nicotine patch, they are expected to have
slightly elevated cotinine levels [43].
Composition of vaginal bacterial communities
DNA extraction from vaginal swabs, PCR amplification
and 454 pyrosequencing of the V1-V3 hypervariable re-
gions of the 16S rRNA genes were performed as previously
described [44] using primers 27 F* [45] and 534R [46].
The QIIME split_libraries.py script (version 1.7.0) [44]
was used to demultiplex and quality filter sequence reads
that had a perfect match to the unique sample-specific bar-
code sequence by: 1) removing primer and barcode se-
quences; 2) truncating reads to the first ambiguous base;
3) truncating reads to the first base of a 25 bp sliding win-
dow where the average quality within the window dropped
below Q25; and 4) including only reads with lengths
between 300–600 bp. Quality filtered reads were de-
replicated (99% similarity) using the UCLUST software
package [47] and potential chimeric sequences were re-
moved using the UCHIME component of UCLUST [48]
prior to taxonomic assignment. Genus level taxonomic
assignments were performed by using the RDP Naïve
Bayesian Classifier [49], and further species level assign-
ments of Lactobacillus sp. were performed using higher
order Markov Chain Lactobacillus species models using
the software speciateIT (speciateIT.sourceforge.net) [44].
For each sample, vectors of phylotype proportions were
clustered into community state types (CSTs) as previously
described by Gajer et al. [50].
Statistical analysis
Fisher’s exact test and logistic regression were used to de-
termine the association between vaginal bacterial CST and
smoking status. Factors collected from questionnaires
that had been identified on the basis of previous literature
and biologic plausibility were evaluated in analyses. To as-
sess differences in the bacterial community structure be-
tween smokers and non-smokers, we also utilized the
classification and regression tree (CART) analysis. Data
were analyzed using STATA/SE 10.0 for Windows (Stata
Corporation, College Station, Texas) and the CART was
performed in R (R Foundation for Statistical Computing,
Vienna, Austria).
Results
Phase A: cross-sectional study
Forty women were enrolled in the cross-sectional study
with an average age of 29 years (SD: 9.03, range 19–45).
Of the 20 smokers, 11 women (55%) reported smoking
1–10 cigarettes per day in the prior 30 days while 9
women (45%) reported 11–20 cigarettes per day. Cotin-
ine and CO levels matched self-reported smoking status
(Table 1). There were no differences in self-reported
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Table 1 Factors associated with smoking status in a cross-sectional study, College Park, MD, n = 40
Non-smokers* Smokers P value**
n % n %
Vaginal community state type (CST)§ 0.04
CST I, L. crispatus-dominated 13 65.0 6 30.0
CST III, L. iners-dominated 4 20.0 4 20.0
CST IV, Lactobacillus-deficient 3 15.0 10 50.0
Nugent Gram stain score 0.02
0-3 17 85.0 10 50.0
4-6 2 10.0 2 10.0
7-10 1 5.0 8 40.0
Vaginal pH† 0.13
<=4 10 50.0 4 20.0
4.1-5.5 1 5.0 2 10.0
4.6-5.0 4 20.0 3 15.0
> = 5.1 5 25.0 11 55.0
Age <0.01
18-28 17 85.0 5 25.0
29-39 1 5.0 7 35.0
40-45 2 10.0 8 40.0
Ethnicity 0.16
African-American 5 25.0 10 50.0
Asian/Pacific islander 3 15.0 1 5.0
Hispanic 3 15.0 0 0.0
Multi-racial 1 5.0 3 15.0
White 8 40.0 6 30.0
Marital status 0.09
Never married 17 85.0 10 50.0
Married 2 10.0 4 20.0
Separated, divorced, widowed 1 5.0 5 25.0
Other 0 0.0 1 5.0
Education, years 0.06
12 0 0.0 5 25.0
13-16 18 90.0 13 65.0
> = 17 2 10.0 2 10.0
Biomarkers of smoking
Cotinine, ng/ml <0.01
0-10 1 5.0 0 0.0
11-30 17 85.0 0 0.0
31-100 2 10.0 0 0.0
101-200 - - - -
201-500 - - - -
501-1000 0 0.0 2 10.0
>1000 0 0.0 18 90.0
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Table 1 Factors associated with smoking status in a cross-sectional study, College Park, MD, n = 40 (Continued)
Carbon monoxide exhalation, ppm <0.01
0-7 20 100.0 0 0.0
8-10 0 0.0 11 55.0
11+ 0 0.0 9 45.0
Self-reported factors
Number of cigarettes per day <0.01
None 20 100.0 0 0.0
1-10 0 0.0 11 55.0
11-20 0 0.0 9 45.0
Symptoms in 24 hours prior to visit
Odor 5 25.0 3 15.0 0.70
Irritation 0 0.0 0 0.0 -
Itching 0 0.0 0 0.0 -
Burning 0 0.0 0 0.0 -
Pain on urination 0 0.0 0 0.0 -
Discharge 5 25.0 4 20.0 >0.99
Diagnoses in the prior 2 months
None 19 95.0 17 94.4 0.73
Bacterial vaginosis 0 0.0 1 5.6
Trichomonas vaginalis and Chlamydia trachomatis 1 5.0 0 0.0
Number of male sex partners in the prior 2 months 0.63
0 5 26.3 4 21.1
1 11 57.9 14 73.7
2-3 3 15.8 1 5.3
Number of female sex partners in the prior 2 months 0.73
0 16 94.1 14 93.3
1 1 5.9 1 6.7
Lifetime number of sex partners <0.01
0-4 8 40 2 11.1
5-7 9 45 1 5.6
8+ 3 15 15 83.3
Hormonal contraception (HC) 0.19
Other, non-HC 6 33.3 8 57.1
Oral contraceptive pill 11 61.1 4 28.6
Injectable 1 5.6 2 14.3
Frequency of vaginal douching in prior 2 months 0.06
None 18 90.0 12 63.2
Every now and then 0 0.0 1 5.3
1–2 times per month 1 5.0 5 26.3
1 time per week 1 5.0 0 0.0
More than one time per week 0 0.0 1 5.3
Sexual activity in prior 24 hours 0.34
No vaginal intercourse 15 75.0 10 50.0
Vaginal intercourse without a condom 3 15.0 6 30.0
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vaginal symptoms between smokers and non-smokers.
One smoker reported a diagnosis of BV in the two
months prior to her visit. Compared to non-smokers,
smokers tended to be older, report a greater number of
lifetime sexual partners, and a greater frequency of vagi-
nal douching.
Vaginal microbiota clustered into three community
state types (CSTs) [44]; two dominated by Lactobacillus
spp. (L. iners (termed CST III), L. crispatus (CST I)), and
one lacking significant numbers of Lactobacillus spp.
and characterized by anaerobic and strictly anaerobic
bacteria (CST-IV) (Figure 1). In prior work we split CST
IV into CST IV-A and IV-B, [50] however, all but two of
the samples were assigned to CST IV-B, and therefore
CST IV-A samples were combined to one CST IV group
as in Ravel et al. [44].
CST was significantly associated with smoking status
(P value =0.04). Fifty percent of smokers versus 15 % of
non-smokers were classified to the low-Lactobacillus
CST IV (Table 1). Similarly, fewer smokers had a L. cris-
patus-dominated CST I (30% in smokers versus 65% in
non-smokers). Smokers tended to have higher Nugent
Gram-stain scores (P value = 0.02) and higher vaginal
pH (P value = 0.13) indicative of BV diagnosis compared
to non-smokers. Among women observed to have high
cotinine concentration (>1000 ng/ml) and CO exhal-
ation (>11 ppm), 56% were categorized to the low-
Lactobacillus CST IV (P value < 0.04). There were also
statistically significant trends for both increasing cotin-
ine concentration and CO exhalation with increasing
Nugent score (P value = 0.004 and P value = 0.005, re-
spectively). Smokers may also have had more sexual
exposures with 83% of smokers versus 15% of non-
smokers reporting a history of eight or more sexual part-
ners (p < 0.01).
In multivariate modeling adjusting for confounders as-
sociated with both BV and smoking (vaginal douching
and lifetime number of sex partners), women who were
observed in the low-Lactobacillus CST IV were 25-fold
more likely to be smokers than those dominated by the
L. crispatus-dominated CST I (adjusted odds ratio (aOR):
25.61, 95% CI: 1.03-636.61); Table 2). Age was non-
significant in the multivariable model although there were
wide divergences in age between smokers and non-
smokers. Ninety percent of the non-smokers were age
18–28 versus 75% of the smokers were age 29–45. The
model was unable to adjust for contraceptive type because
eight of the 40 women declined response on the survey
and therefore further limited the sample size of the multi-
variate model.
In the CART analysis, bacteria from the genera Peptos-
treptococcus and Veillonella were identified as the most
important bacterial predictors for smoking status among
the 133 bacteria observed.
Phase B: a pilot longitudinal study of smoking cessation
Of the nine women who enrolled in Phase B, four com-
pleted the 12-week study, three discontinued at 5–8
weeks, and two dropped out immediately. None of the
women in Phase B reported a clinician’s diagnosis of
symptomatic BV or antibiotic use during the study. Cotin-
ine and CO levels of enrolled women suggest they main-
tained nicotine patch use (high cotinine levels) and quit
smoking or reduced smoking (low CO levels) (Figure 2).
Even among those women who were lost to follow-up at
weeks 5–8, cotinine and CO levels suggest good compli-
ance with smoking cessation (data not shown).
Of the four women who completed the 12-week study,
three entered the study with high Nugent scores and va-
ginal microbiota belonging to the low-Lactobacillus CST
IV (Figure 2). Of these three women, one woman (ID#1)
demonstrated a possible response to smoking cessation.
At week 10, coinciding with completion of the nicotine
patch and smoking cessation program, her CSTs
switched from CST IV to CST III (a L. iners-dominated)
and CST I (L. crispatus-dominated) with a concomitant
drop in Nugent scores. She did not report a vaginitis
diagnosis during the study or in the two months prior to
study entry, nor any antibiotic use during the study or
any change in behaviors which she documented on the
Table 1 Factors associated with smoking status in a cross-sectional study, College Park, MD, n = 40 (Continued)
Vaginal intercourse with a condom 2 10.0 4 20.0
Menstrual hygiene in prior 24 hours >0.99
Sanitary napkin, no tampon 11 57.9 11 64.7
Sanitary napkin only 2 10.5 1 5.9
Tampon only 4 21.1 4 23.5
Tampon and sanitary napkin 2 10.5 1 5.9
§CST defined by Ravel et al.44
*Non-smoker defined by self-report and 0–200 ng/ml on saliva cotinine test (NicAlert®) and 0–7 ppm on carbon monoxide exhalation (ppm), Bedfont
Micro Smokerlyzer®.
**P- values determined by Fisher's exact test.
†CarePlan® VpH Test Glove.
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daily diaries. She reported intermittent vaginal odor and
discharge on daily diaries but had no such complaints in
the final two weeks of observation when she had ceased
smoking, finished the nicotine patch protocol and
switched to the Lactobacillus-dominated CSTs. The
other 2 women (ID#s 2 and 3) fluctuated between CST
IV and CST III. The fourth woman (ID#6) had low
Nugent scores with L. crispatus-dominated CST I
throughout (Figure 2). Among the three women that did
not complete follow-up, Nugent scores fluctuated be-
tween low and intermediate categories. Longitudinal
multivariate modeling was not possible in Phase B due
to the small sample size (n = 4) of this pilot study, and
therefore, we are limited to descriptive findings.
Discussion
The cross-sectional study (Phase A) suggests that
women who smoke cigarettes are significantly more
likely to have a vaginal microbiota characterized by low
proportions of Lactobacillus spp. In Phase B, with one of
three women shifting from a vaginal Lactobacillus-defi-
cient CST to a Lactobacillus-dominated CST during
smoking cessation without the aid of antibiotics, we
hypothesize that smoking cessation could benefit some
women struggling with recurrent BV. In order to estab-
lish the causal association that smoking directly affects
the vaginal microbiome and recurrence of BV, a larger
smoking cessation study design is needed that also in-
cludes clinical evaluation for BV.
Several participants in Phase B fluctuated between a
low-Lactobacillus state and a L. iners dominated CST
with ID#1 appearing to transition fully to a L. iners-
dominated CST. There has been recent species-specific
attention to L. iners [51,52] L. iners is commonly found
in the vagina [44] and has been associated with both BV
and healthy states [53-56]. In addition, L. iners is often
the first Lactobacillus species to recover after treatment
for BV [46,56]. Our group’s prior work suggest there are
strains of L. iners which are highly stable over time while
others are associated with a rapidly changing vaginal
microbiota tending toward a BV state [46,50]. Ongoing
work is evaluating the genomic heterogeneity of L. iners
and if different strains are associated with STI or BV
outcomes [57].
Figure 1 Heatmap of bacterial relative abundance from 20 smokers and 20 non-smokers sampled cross-sectionally. Each vertical line
represents the bacterial composition of one participant. Smoking status is displayed at top in red and green. Bacterial community state type (CST)
are determined vectors of phylotype proportions as previously described by Gajer et al. [50].
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This pilot study provides important preliminary data
for future studies. Attrition was high among participants
attempting smoking cessation in Phase B (55%), al-
though those who remained in the study were very com-
pliant with smoking cessation, nicotine patch use,
attending weekly counseling sessions, and daily collec-
tion of vaginal swabs, vaginal pH, vaginal smears and
diary entries. Women who were lost to follow-up were
also compliant with smoking cessation as indicated by
biomarkers. Loss to follow-up rates greater than 30%
are not unusual in smoking cessation trials [58-61], and
therefore a future study may need to recruit two-fold
more women as our study indicates. Weekly visits con-
firmed that samples were collected in the week stipu-
lated. We advocate that future studies include frequent
self-collection of vaginal swabs (daily or 2–3 times
weekly) with careful collection of the menstrual cycle,
antibiotic use and behavioral data [50,62,63]. In addition,
longer duration of follow-up (>12 weeks) is likely neces-
sary to capture all women if their microbiome is to re-
bound to Lactobacillus-dominated CSTs.
There are a number of limitations to this study. The re-
search was designed as a pilot, and therefore, sample size
and funds were limited. We were unable to conduct broad
testing for sexually transmitted infections, and larger stud-
ies may be able to detect other known CSTs, such as CSTs
dominated by L. gasseri and L. jensenii. It should also be
noted that there are known racial and ethnic differences
in nicotine metabolism, which may affect biomarkers of
smoking exposure [64-66]. Cotinine and carbon monoxide
levels matched self-report of smoking in our study. Also
due to sample size, we were unable to control for import-
ant confounders. For example, another important factor
which may be driving the inverse association between
Lactobacillus-dominated CSTs (and also Nugent scores)
with smoking status is hormonal contraception (HC). Use
of HC in most epidemiological studies has been associated
with a reduced risk of bacterial vaginosis [67]. Sixty per-
cent of non-smokers versus 25% of smokers were using
HC. The differences in HC use likely reflects clinicians’
prescribing patterns in which smokers are not prescribed
HC due to potential cardiovascular side effects [68]. Fur-
ther, smokers tended to be older (over age 40 and possibly
peri-menopausal) and therefore less likely to use HCs. It
was not possible for this analysis to use HC in statistical
modeling because eight of the 40 women in Phase A de-
clined to answer the contraceptive questions and the sam-
ple size became prohibitive. In addition, HC use was not
different between smokers and non-smokers in univariate
analysis (P value =0.19). It remains important for future
studies to collect HC formulation data and control for it
in analysis.
It was also surprising to observe 5% of the non-
smokers versus 40% of smokers had high Gram stain
Table 2 Odds ratios for factors associated with smoking status, College Park, MD, n = 40
OR 95% CI P value Adjusted OR 95% CI P value
Community state type (CST), dominant bacteria§
CST-I, L. crispatus-dominated REF - - - REF - - -
CST-III, L. iners-dominated 2.17 0.40 11.74 0.37 2.66 0.19 38.04 0.47
CST-IV, Lactobacillus-deficient 7.22 1.44 36.22 0.02 25.61 1.03 636.61 0.05
Age
18-28 REF - - -
29-39 23.80 2.34 242.29 0.01 - - - -
40-45 13.60 2.15 85.86 0.01 - - - -
Education, years 0.82 0.61 1.10 0.18 - - - -
Douching, past 2 months 5.25 0.93 29.70 0.06 0.81 0.05 13.61 0.88
Currently menstruating 1.00 0.29 3.45 1.00
Lifetime number of sex partners
0-4 REF - - -
5-7 0.44 0.03 5.88 0.54 0.31 0.01 9.84 0.50
8 or more 20.00 2.75 145.48 0.00 40.70 2.46 674.00 0.01
Sexual activity in prior 24 hours
No vaginal intercourse REF - - - - - - -
Vaginal intercourse with no condom 3.00 0.61 14.86 0.18 - - - -
Vaginal intercourse with a condom 3.00 0.46 19.59 0.25 - - - -
§CST defined by Ravel et al.44
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scores indicative of BV. This could have been the result
of recruitment of “healthier” women than an average
non-smoking cohort, and therefore, the non-smoking
group was biased by women with Lactobacillus-domi-
nated microbiota. However, non-smokers and smokers
were recruited using the same methods of advertising
and outreach, and more importantly, our data demon-
strated that there were statistically significant dose-
responses for increasing cotinine concentration and CO
exhalation with increasing Nugent score. Numerous stud-
ies indicate BV is more common in smokers than non-
smokers, smoking has a dose-dependent relationship with
BV and the associations persist after controlling for con-
founders [1-12]. The current study also utilized saliva co-
tinine and carbon monoxide exhalation measures (which
prior studies have not collected) coupled with extensive
surveys to properly categorize women as smokers and
non-smokers. A larger study with more representative
sampling, coupled with biomarker detection of smoking,
could resolve this issue.
A major strength of this study is that we are able to pro-
vide preliminary data for future studies and self-report of
smoking status was confirmed by biomarkers. The study
also utilized comprehensive questionnaires, weekly coun-
seling in smoking cessation and high-throughput DNA se-
quencing technologies. Participants self-collected vaginal
swabs daily so the dynamics of the microbiota could be in-
tensively followed in smoking cessation.
Conclusion
To our knowledge, this is the first study to assess differ-
ences in the vaginal microbiota between smokers and
non-smokers and to begin to assess how smoking cessa-
tion affects the vaginal microbiome. We found smoking is
associated with a vaginal microbiota which has low pro-
portions of Lactobacillus spp, however future research is
needed to establish if smoking is causally related to BV
and to assess if smoking interventions could positively
affect the vaginal microbiome. If smoking cessation proves
to reduce incidence, persistence or recurrence of BV, it
Figure 2 Longitudinal trajectories of the four women who completed the 12-week smoking cessation intervention. See key for Nugent
Gram stain score, carbon monoxide, cotinine and bacterial community state type assignments.
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may also offer an additional incentive for women to
quit smoking.
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